Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a treatment protocol with blinatumomab for infants under 1 year old diagnosed with acute lymphoblastic leukemia ALL or mixed phenotype acute leukemia that have a specific unfavorable genetic change called KMT2A-rearrangement. The study aims to improve outcomes for these infants by adding blinatumomab to standard therapy. This is a Phase 3 interventional study sponsored by the Princess Maxima Center for Pediatric Oncology. All eligible infants will receive one cycle of blinatumomab after their initial induction therapy. Medium risk patients who respond well to the first cycle may receive a second cycle of blinatumomab replacing a chemotherapy course after consolidation therapy. High risk patients or those with insufficient response will be considered for allogeneic stem cell transplantation after the first cycle. The response to blinatumomab will be measured by minimal residual disease MRD levels. During the study, participants will be monitored closely with laboratory tests and assessments including MRD evaluations. Researchers will track event-free survival over 5 years and overall survival, relapse, and adverse events for up to 8 years. The total participation can last several years to capture long-term outcomes and safety. Parents or guardians provide consent and the study offers continuous monitoring to better understand treatment effects in this vulnerable population.